4//SEC Filing
RUBIN PAUL D 4
Accession 0001210905-25-000004
CIK 0001709941other
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 6:20 PM ET
Size
9.2 KB
Accession
0001210905-25-000004
Insider Transaction Report
Form 4
RUBIN PAUL D
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-04$4.11/sh+68,897$283,167→ 68,897 total - Sale
Common Stock
2025-12-04$10.19/sh−68,897$701,909→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-04−68,897→ 21,736 totalExercise: $4.11Exp: 2030-06-30→ Common Stock (68,897 underlying)
Footnotes (3)
- [F1]The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.96 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- [F3]This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
Documents
Issuer
BioAge Labs, Inc.
CIK 0001709941
Entity typeother
Related Parties
1- filerCIK 0001210905
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 6:20 PM ET
- Size
- 9.2 KB